February 1, 2012

As part of DSN's Executive Retailer Viewpoint series, DSN sat down with Jason Reiser, VP health and wellness, ops/compliance at Sam's Club, at DSN's Industry Issues Summit to discuss how to better engage customers and the impact of the economy on business in 2012.

January 18, 2012

In an effort to tap into the minds of some of the industry's top executives, Drug Store News recently sat down and talked with some of these leaders in a multipart executive viewpoint video series.

December 16, 2014

 Greenstone announced the launch of celecoxib — the authorized generic version of Pfizer's Celebrex — to its line of generic pharmaceuticals. 

December 16, 2014

Novartis on Tuesday received approval from the Food and Drug Administration for Signifor long-acting release (pasireotide) for injectable suspension, for intramuscular use. 

 

December 11, 2014

Lupin Pharmaceuticals launched the authorized generic version of Celebrex capsules in 50-, 100-, 200- and 400-mg dosage strengths. 

December 10, 2014

Mylan on Wednesday launched its celecoxib capsules in 50-, 100-, 200- and 400-mg dosage strengths. The drug is one of the first available generic versions of Celebrex capsules from Pfizer.

December 10, 2014

Teva Pharmaceutical Industries on Wednesday announced the launch of generic Celebrex (celecoxib) capsules in the United States. The company is offering the capsules in 50-,100-, 200- and 400-mg dosage strengths. 

 

December 9, 2014

Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva. 

December 4, 2014

Diplomat Pharmacy announced Wednesday that it has been selected to Pfizer's limited-distribution panel for Xalkori, Bosulif, Inlyta and Sutent.

November 20, 2014

Moberg Pharma AB on Thursday announced that Jeff Vernimb has been named general manager for its U.S. operations and a member of Moberg's management team, effective Dec. 15.

 

November 18, 2014

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries, on Tuesday announced that Health Canada has approved its application for PrTeva-Celecoxib, the generic equivalent of PrCelebrex.

October 30, 2014

Bridgestone Americas announced that TJ Higgins has been named president of the consumer U.S. and Canada divisions for the company's tire operations, effective Nov. 3. 

October 24, 2014

Pfizer on Thursday announced that the U.S. District Court for the District of Delaware upheld its basic patent and the L-malate salt patent covering Sutent (sunitinib malate) capsules.

October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

October 15, 2014

The big story in the digestives space is the switch and launch in May of Pfizer’s Nexium 24HR. In a little more than 10 weeks on the shelf, the brand has generated $53.6 million in sales across total U.S. multi-outlets for the 52 weeks ended Aug. 10, according to IRI. 

September 25, 2014

Pfizer announced on Thursday that it has completed its acquisition of the pharmaceutical development company, InnoPharma, following receipt of U.S. regulatory approval from all government authorities required by the agreement and other closing conditions.

September 16, 2014

More than 75 locally-owned community pharmacies throughout Arkansas are enhancing patient care by participating in a unique nine-month medication adherence program.

September 1, 2014

Pfizer and Protalix BioTherapeutics last week announced that the Food and Drug Administration approved Elelyso (taliglucerase alfa) for injection for pediatric patients.

September 1, 2014

Pfizer last week announced that the Food and Drug Administration has granted fast track designation to the company’s investigational Clostridium difficile (C. difficile) vaccine candidate (PF-06425090). 

August 20, 2014

In May 2014, Pfizer introduced Nexium 24HR, one of the top-selling acid blockers, over the counter in the United States.

August 20, 2014

Pfizer successfully switched Nexium to over-the-counter in late May, and with that brought a $6 billion book of prescription business to antacid aisles, according to IMS Health data compiled over 2012.

August 19, 2014

"The consumer healthcare market has experienced a steady stream of mergers and acquisitions in recent years. Some of this has created small ripples — like pebbles being gently tossed into still waters. Then there are the mega-mergers that have had a tsunami-like effect," writes Dave Wendland, Hamacher Resource Group VP, in his latest blog entry.

August 15, 2014

Pfizer’s Prevnar 13 vaccine for pneumonia has been recommended for use by patients 65 years old and up by the Centers for Disease Control and Prevention’s immunization practices advisory committee. 

August 11, 2014

Sanofi on Monday acquired the rights to Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with Type 1 and Type 2 diabetes, from MannKind in a deal that could be worth as much as $925 million.